<DOC>
	<DOCNO>NCT02765165</DOCNO>
	<brief_summary>This multicenter , open-label , Phase 1/2 , dose-escalation dose expansion study CXCR4 inhibitor , USL311 , alone combination lomustine subject advance solid tumor ( Phase 1 ) subject relapsed/recurrent GBM ( Phase 2 ) . The study design explore safety , tolerability , pharmacokinetics , preliminary efficacy USL311 alone combination lomustine .</brief_summary>
	<brief_title>Phase 1/2 Study USL311 Alone Combination With Lomustine Subjects With Advanced Solid Tumors Relapsed/Recurrent Glioblastoma Multiforme ( GBM )</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Lomustine</mesh_term>
	<criteria>All Subjects : 1 . Provide sign date informed consent prior studyspecific screening procedure 2 . ≥ 18 year old 3 . Karnofsky performance status ( KPS ) ≥ 70 4 . Must adequate bone marrow renal/hepatic function within protocol specify limit 5 . Diseasefree period &gt; 2 year previous malignancy , exclude curatively treat basal cell carcinoma , squamous cell carcinoma skin , carcinoma situ cervix . Subjects prostate cancer Stage 1 require treatment may also include 6 . Women men must use protocol approve method contraception 7 . Must able willing comply study visit schedule study procedures 8 . Must available archive tumor tissue willing able provide consent study access tissue For Phase 1 Subjects Only : 9 . Histologically cytologically document diagnosis solid tumor standard therapy recognize fail intolerant standardofcare treatment 10 . Inoperable metastatic locally advanced , unresectable disease 11 . Subjects may either evaluable measurable disease 12 . Subjects treat ( surgically excise irradiate ) stable brain metastasis eligible long subject adequately recover treatment treatment ≥ 28 day prior initiation study drug ( ) baseline brain compute tomography ( CT ) contrast magnetic resonance imaging ( MRI ) ≤ 14 day initiation study drug negative new brain metastasis For Phase 2 Subjects Only : 13 . Histologically confirm diagnosis GBM 14 . Subjects must document recurrence firstline treatment 15 . Prior firstline treatment must include radiation temozolomide 16 . Subject suitable reresection , per Investigator discretion , component clinical care 17 . No one prior resection ( Note : biopsy count prior resection ) All Subjects 1 . Subjects recent systemic anticancer therapy , interventional device treatment and/or radiotherapy either within 14 day prior first dose study drug ( ) recover ( grade ≤ 1 ) clinically significant toxicity relate prior therapy 2 . Subjects major surgery ( include reresection surgery require Phase 2 ) within 28 day prior first dose study drug ( ) , minor surgery within 14 day prior first day study drug ( ) 3 . Subjects take protocol prohibit medication within 14 day prior initiate study drug ( ) treatment 4 . Subjects treat investigational agent investigational interventional device within 21 day prior first dose study drug ( ) 5 . History significant cardiac disease 6 . Pregnant breastfeed 7 . Any significant comorbid condition opinion Investigator would impair study participation cooperation For Phase 1 Subjects Only : 8 . Subjects lymphoma primary cancer For Phase 2 Subjects Only : 9 . Subjects unable unwilling consent provision resect tissue surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Phase 1</keyword>
	<keyword>Phase 2</keyword>
	<keyword>Glioblastoma Multiforme</keyword>
	<keyword>Glioblastoma</keyword>
	<keyword>GBM</keyword>
	<keyword>Brain Tumor</keyword>
	<keyword>Brain Cancer</keyword>
	<keyword>Tumor</keyword>
	<keyword>Solid Tumor</keyword>
	<keyword>Tumour</keyword>
	<keyword>Lomustine</keyword>
	<keyword>CCNU</keyword>
	<keyword>CXCR4</keyword>
	<keyword>Phase 1 Clinical Trial</keyword>
	<keyword>Phase 2 Clinical Trial</keyword>
</DOC>